Korro Bio (NASDAQ:KRRO) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Korro Bio (NASDAQ:KRRO) in a report published on Tuesday, Benzinga reports. HC Wainwright currently has a $100.00 price target on the stock.

Several other analysts also recently weighed in on the company. Royal Bank of Canada dropped their price objective on Korro Bio from $105.00 to $95.00 and set an outperform rating for the company in a research report on Wednesday, August 14th. William Blair started coverage on shares of Korro Bio in a research note on Wednesday, August 14th. They issued an outperform rating and a $180.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Korro Bio currently has an average rating of Buy and an average target price of $135.00.

Korro Bio Trading Up 4.8 %

Shares of Korro Bio stock opened at $38.50 on Tuesday. The firm’s 50-day moving average price is $43.73 and its two-hundred day moving average price is $51.31. Korro Bio has a 12-month low of $9.15 and a 12-month high of $97.91.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($2.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04). Equities research analysts anticipate that Korro Bio will post -10.29 EPS for the current year.

Hedge Funds Weigh In On Korro Bio

Large investors have recently bought and sold shares of the company. Atlas Venture Life Science Advisors LLC bought a new stake in shares of Korro Bio during the fourth quarter worth about $53,648,000. Eventide Asset Management LLC bought a new stake in Korro Bio during the 4th quarter worth approximately $26,185,000. 72 Investment Holdings LLC acquired a new position in Korro Bio in the 4th quarter valued at approximately $13,269,000. Point72 Asset Management L.P. raised its stake in shares of Korro Bio by 71.6% during the second quarter. Point72 Asset Management L.P. now owns 456,085 shares of the company’s stock valued at $15,448,000 after acquiring an additional 190,259 shares during the last quarter. Finally, Driehaus Capital Management LLC acquired a new position in shares of Korro Bio during the second quarter worth $3,958,000. 13.18% of the stock is currently owned by institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).